Full Press Release Details
regeneron expands clinical stage obesity portfolio with strategic in licensing of novel dual glp 1 gip receptor agonist.
REGN
regeneron expands clinical stage obesity portfolio with strategic in licensing of novel dual glp 1 gip receptor agonist
Key Takeaway: regeneron expands clinical stage obesity portfolio with strategic in licensing of novel dual glp 1 gip receptor agonist